Patents by Inventor Thomas Schmehl

Thomas Schmehl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230062605
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Application
    Filed: October 17, 2022
    Publication date: March 2, 2023
    Applicant: United Therapeutics Corporation
    Inventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
  • Publication number: 20220323459
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Application
    Filed: May 16, 2022
    Publication date: October 13, 2022
    Applicant: United Therapeutics Corporation
    Inventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
  • Publication number: 20220218720
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Application
    Filed: March 29, 2022
    Publication date: July 14, 2022
    Applicant: United Therapeutics Corporation
    Inventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
  • Patent number: 11357782
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: June 14, 2022
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Publication number: 20220008436
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 13, 2022
    Applicant: United Therapeutics Corporation
    Inventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
  • Patent number: 10821116
    Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: November 3, 2020
    Assignee: VECTURA GMBH
    Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
  • Patent number: 10716793
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: July 21, 2020
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Publication number: 20200171044
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Application
    Filed: January 31, 2020
    Publication date: June 4, 2020
    Applicant: United Therapeutics Corporation
    Inventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas Schmehl, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
  • Publication number: 20190365778
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Application
    Filed: August 9, 2019
    Publication date: December 5, 2019
    Applicant: United Therapeutics Corporation
    Inventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
  • Patent number: 10376525
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: August 13, 2019
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Patent number: 10258570
    Abstract: The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 ?m and 5 ?m, preferably between 0.2 ?m and 2.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: April 16, 2019
    Assignee: Lung Biotechnology Inc.
    Inventors: Tobias Gessler, Thomas Schmehl, Monika Rieger
  • Publication number: 20170014424
    Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 19, 2017
    Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
  • Patent number: 9486427
    Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. The administration is by inhalation over a short period of time, which is patient-friendly, effective, and well tolerated. Inhalation may, for example, be achieved using an efficient nebulizer based on the vibrating mesh technology.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: November 8, 2016
    Assignee: Vectura GMBH
    Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
  • Patent number: 9358240
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: June 7, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Publication number: 20160143868
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Application
    Filed: February 1, 2016
    Publication date: May 26, 2016
    Applicant: United Therapeutics Corporation
    Inventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
  • Patent number: 9339507
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: May 17, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Publication number: 20150290153
    Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. The administration is by inhalation over a short period of time, which is patient-friendly, effective, and well tolerated. Inhalation may, for example, be achieved using an efficient nebulizer based on the vibrating mesh technology.
    Type: Application
    Filed: September 12, 2013
    Publication date: October 15, 2015
    Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
  • Publication number: 20140155486
    Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.
    Type: Application
    Filed: April 26, 2012
    Publication date: June 5, 2014
    Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
  • Publication number: 20140127311
    Abstract: The present invention provides biocompatible nano-polymer particles which are composed of a biocompatible polymer, a stabilizer and an active agent for the treatment of pulmonary hypertension or erectile dysfunction and which can be used to produce a pharmaceutical preparation for the treatment of pulmonary hypertension or erectile dysfunction. Biocompatible nano-polymer particles of this invention have a diameter ranging from 10 nm to 10 ?m auf, a stabilizing layer thickness between 0 and 50 nm, contain between 0 and 50% of an active agent for the treatment of pulmonary hypertension or erectile dysfunction, are nebulizable and continuously release the active agent over a period of up to 48 hours. Biocompatible nano-polymer particles of this invention can be synthesized for example using the emulsion technique known to the expert with subsequent solvent evaporation or via spray drying.
    Type: Application
    Filed: May 23, 2012
    Publication date: May 8, 2014
    Applicant: JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
    Inventors: Moritz Beck-Broichsitter, Thomas Schmehl, Tobias Gessler, Thomas Kissel
  • Publication number: 20140099379
    Abstract: The present invention provides stabilizers for the coating of biocompatible nano- and microparticles which prevent aggregation of the particles during preparation, storage as well as before and after nebulization and which are suitable to be utilized for the manufacture of a pharmaceutical preparation for pulmonary application. Biocompatible nano- and microparticles of this invention have a stabilizer layer thickness ranging from 1 to 200 nm and contain an active substance. Said biocompatible nano- and microparticles of this invention can be synthesized for example using the emulsion method known to the expert with subsequent coating by mixing of uncoated particles with the stabilizer, by chemical vapor deposition, by spraying or by covalent attachment.
    Type: Application
    Filed: May 23, 2012
    Publication date: April 10, 2014
    Applicant: JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
    Inventors: Moritz Beck-Broichsitter, Tobias Gessler, Thomas Schmehl